Questo sito utilizza cookie tecnici, cookie Analytics e cookie di terze parti per il funzionamento del sito e per migliorare l’esperienza utente.
Cliccando su Accetto si presta il consenso all’uso dei cookie. Leggi l’informativa.

Privacy | Cookie Policy

Renal cell carcinoma cell line and use thereof

Renal cell carcinoma (RCC) is the third most common type of urological tumor after prostate and bladder tumors. The treatment options for RCC are surgery, radiation therapy, chemotherapy, immunotherapy, or combinations of these. Chemotherapy has not yielded satisfactory results showing that RCC is highly resistant to a range of chemotherapeutic agents administered either in combination or not. Starting from the evidences that RCC expresses antigen recognized by immune system, particularly by cytotoxic T- lymphocytes (CTLs) which can enable the development of a tumor - rejection - type immune response, the new RCC line is capable of activating the immune system in an antigen specific manner.
State of development
Industrial application
"This cell line can be used: 1. as lysate in DC-based therapeutic vaccines in RCC patients. 2. for the development of high-throughput screens that will be useful for clinical diagnostic purposes. The impact accounted for the patenting of this renal immunogenic cell line is to undertake a co-development of DC-based vaccine to produce the antigenic format Elthem-derived (lysate) for DC-loading under GMP conditions and to produce the GMP vaccine for the treatment of RCC patients
Advantage factor
"The main characteristic of this new cell line is its immunogenicity. The cell line and its derivates is able to activate the immune system and in particular dendritic cells, lymphocytes and CD4+ and CD8+ T cells inducing an antigen-specific response in patient suffering from kidney tumor. Advantages: New adjuvant treatment; High immunogenicity State of development: Preclinical (in vitro test) Actual status: Licensed to European Collection of Cell Cultures (ECACC), Public Health England, UK
Proposal cooperation
Know-how transfer